Delivery Order SPE2DB22D1041-SPE2DB25FUBS5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Zepbound 15 mg/0.5 ml pen injectors with a ceiling value of $20,970.99. This is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- The Defense Logistics Agency awarded a delivery order valued at $9,527.57 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 ml pen injectors on August 1, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement and is scheduled for completion by August 4, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,048.25 for Zepbound 10 mg/0.5 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $12,539.80 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on July 31, 2025. This firm fixed-price, competitively awarded delivery order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, with an ultimate completion date of August 1, 2025. The contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,812.90 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and...
- The Defense Logistics Agency has awarded a $40,331.20 delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 10 mg/0.5 mL pen injectors, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 22, 2025, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the open competition process through which...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This firm fixed price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers pharmaceutical supply to support federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order valued at $6,518.07 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order executed under an existing contract vehicle and requires fulfillment within an...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBS5Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $22,115.85 on September 4, 2025, for the supply of Zepbound 15 mg/0.5 ml pen injectors. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. This delivery order is issued under AmerisourceBergen's comprehensive $999,999,999 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for military and federal healthcare systems, supplying a broad portfolio of pharmaceutical products, medical devices, and healthcare commodities. The DLA Troop Support Medical contract vehicle enables the company to support Defense Health Agency operations and other federal healthcare programs globally with medications spanning multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.1k | 9/4/25 |